Virginia Board of Medicine Practitioner Information

Home Icon Home

Search Icon Search

Disclaimer Icon Disclaimers

Links Icon Links

Glossary Icon Glossary

Help Icon Questions


Printer Friendly Version Printer Icon
 

Corey Allan Carter, MD

LICENSE # 0101236858
 
Issue Date: 7/9/2004
Expiration Date: 3/31/2026
Status: Current Active


General InformationEducationCertifications & Practice AreaInsuranceHonors & AwardsAcademic Appointments & PublicationsProceedings, Actions & ConvictionsPaid Claims
Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.


Academic Appointments
Last Updated 2/12/2024
Uniformed Services University Of The Health Sciences F. Edward Hébert School Of Medicine - Bethesda MD
Rank: Instructor
Years: 2004-2009

Uniformed Services University Of The Health Sciences F. Edward Hébert School Of Medicine - Bethesda MD
Rank: Assistant Professor
Years: 2009-Present

Academic Appointments - Non-US
Last Updated 2/12/2024
None Reported
Publications
(up to ten in the last five years)
Last Updated 2/12/2024
Activation of Prostate-Specific Antigen Precursor (pro-PSA) by Prostin, a novel Human Prostatic Serine Protease Identified by Degenerate PCR
Biochemistry
40(6): 1679-1687
Date: 02 2001

Temporary-Defferred Therapy (TDT) (Watchful Waiting) in Low Risk Localized Prostate Cancer in Men under age 70 in the PSA Era: Results from the DOD CPDR National Database
Journal of Clinical Oncology
1:21(21): 4001-4008
Date: 11 2003

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Lancet Oncol. 2015 Feb;16(2):177-86. doi: 10.1016/S1470-2045(14)71181-7. Epub 2015 Jan 13.
Date: 01 2015
www.ncbi.nlm.nih.gov/pubmed/25592632

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
J Clin Oncol. 2015 Mar 20;33(9):1000-7. doi: 10.1200/JCO.2014.58.2007. Epub 2015 Feb 9.
Date: 03 2015
www.ncbi.nlm.nih.gov/pubmed/25667274

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Lancet Oncol. 2015 Sep;16(9):1133-42. doi: 10.1016/S1470-2045(15)00089-3. Epub 2015 Aug 19.
Date: 09 2015
www.ncbi.nlm.nih.gov/pubmed/26296952

Survival and Racial Differences of Non-Small Cell Lung Cancer in the United States Military.
J Gen Intern Med. 2015 Oct;30(10):1406-12. doi: 10.1007/s11606-015-3280-z. Epub 2015 Mar 25.
Date: 10 2015
www.ncbi.nlm.nih.gov/pubmed/25805503

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
Ann Oncol. 2016 Apr;27(4):693-9. doi: 10.1093/annonc/mdw008. Epub 2016 Jan 22.
Date: 01 2016
www.ncbi.nlm.nih.gov/pubmed/26802155